Home/Thylacine Biosciences/Tom Monath, MD

TM

Tom Monath, MD

Chief Medical Officer

Thylacine Biosciences

Therapeutic Areas

Infectious Disease Respiratory Diseases

Thylacine Biosciences Pipeline

Drug	Indication	Phase
Undisclosed Commercial Antiviral(s)	Persistent endemic respiratory viruses	Pre-clinical
Undisclosed Biothreat Antiviral(s)	High-consequence viral pathogens with pandemic potential	Pre-clinical

Leadership Team at Thylacine Biosciences

Anne Moscona, MD

Inventor, Scientific Advisor

Matteo Porotto, PhD

Inventor, Scientific Advisor

Elma Hawkins, PhD, MBA

Chairwoman of the Board

Daniel Graifman, MBA

View full Thylacine Biosciences profile